parp1-inhibitor
(2)
Synnovation Therapeutics
Synnovation Therapeutics is a Wilmington, Delaware precision medicine company building small-molecule cancer drugs aimed at validated oncology targets where greater potency and selectivity could beat the current standard of care. Founded in 2024 by a team of former Incyte medicinal chemistry leaders, it launched with a $102 million Series A led by Third Rock Ventures. Its lead programs are SNV1521, a CNS-penetrant, highly selective PARP1 inhibitor, and SNV4818, a mutant-selective PI3K-alpha inhibitor whose subsidiary Pikavation Therapeutics was acquired by Novartis in March 2026 for $2 billion upfront.
Wenqing Yao
Wenqing Yao is the founder and CEO of Synnovation Therapeutics, a precision-oncology biotech in Wilmington, Delaware. A medicinal chemist by training, he spent nearly two decades at Incyte building and leading its discovery chemistry engine, a stretch that produced five FDA-approved drugs including Jakafi. In 2021 he left to start Synnovation, which launched publicly in January 2024 with a $102 million Series A to advance best-in-class small molecules against highly validated targets, led by a CNS-penetrant, isoform-selective PARP1 inhibitor and a mutant-selective PI3K-alpha inhibitor.